“An outstanding project within the VISICORT consortium is a Phase 1B clinical trial testing the safety and feasibility of intravenously administered allogeneic mesenchymal stromal cells (allo-MSC) as an immunotherapy for patients at high risk of keratoplasty. Following recent regulatory and ethical approval for the first clinical study on the risk therapy for cell therapy in risk keratoplasty, the inclusion of the first patients is imminent.”
VISICORT’s clinical trial is listed on the BeCAT web page. BeCAT, the Berlin Center for Advanced Therapy is Charité’s an amalgamation of cross-disciplinary project teams that develop and manufacture Advanced Therapy Medicinal Products (ATMP) for somatic cell therapeutics, gene therapeutics, and tissue engineering biotechnological tissue. Read about BeCAT and VISICORT (in German and English) here.
Learn more about VISICORT at www.visicort.eu
Follow its Research Gate profile here.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602470. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.